BG Medicine Posts 20 Percent Drop in Q2 Revenues | GenomeWeb

NEW YORK (GenomeWeb News) – BG Medicine today reported second quarter revenues of $799,000, down 20 percent from $1.0 million in the second quarter of 2013.

The revenues consisted solely of product revenues from sales of the company's BGM Galectin-3 test. Product revenues were down 18 percent from $972,000 in Q2 2013.

The company reported no service revenues. It reported $34,000 in service revenues in the year-ago period.

BG also lowered its full-year 2014 guidance, noting that it no longer expects 2014 revenues to exceed 2013 revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.